1. European Medicines Agency. (2009). ICH guideline M3(R2) on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002720.pdf.
2. European Medicines Agency. (2007). Regulation on advanced therapy medicinal products. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2007:324:0121:0137:en:PDF.
3. European Medicines Agency. (2007). Guideline on the nonclinical studies required before first clinical use of gene therapy medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003743.pdf.
4. European Medicines Agency. (2015). Note for guidance on the quality, preclinical and clinical aspects of gene transfer medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/05/WC500187020.pdf.
5. Food and Drug Administration. (2013). Guidance for industry preclinical assessment of investigational cellular and gene therapy products. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.